Effect of Vernonia Cinerea Lozenges as a Smoking Cessation Aid in Patients With Non-communicable Diseases

Smoking Cessation Clinical Trial

Official title:

Effect of Vernonia Cinerea Lozenges as a Smoking Cessation Aid in Patients With Non-communicable Diseases

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06268002
• Other study ID #: 5876557033
• Status: Completed
• Phase: N/A
• Start date: September 1, 2017
• Est. completion date: December 31, 2021

Study information

• Verified date: January 2018
• Source: Chulalongkorn University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Vernonia cinerea is an herbal which has been recorded in many Thai herbal formulation and Thai traditional medicine has used this herbal for treating various diseases included hypertension, asthma, fever, hepatitis, kidney stone and smoking cessation. Now aday there are more interest for using Vernonia cinerea as a medication to aid smoker to quit smoking because it is cheaper than other current therapeutic medications. The objective of this study is to evaluate efficacy and safety of Vernonia cinerea lozenge for smoking cessation when compared to placebo.

Description:

This study is a multicenter randomized, paralleled, double blind, controlled trial. This study will include 260 patients from Lerdsin hospital, Chest institute, Phramongkutklao hospital, Maharaj Nakorn Chiang Mai Hospital and Paolo Memorial Phaholyothin hospital who would like to quit smoke. Patients will be assigned into two groups, Vernonia cinerea group (n=130) and placebo group (n=130), both groups will be instructed to take one lozenge three times a day for three months. The two groups will receive individual counseling about smoking cessation technique by trained healthcare professional on every visit. The main primary outcome for this study is continuous abstinence rate (CAR), define as self-report of no cigarette smoking, not even a puff since target quit date, plus passed biochemical validation for 1 month.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 93
• Est. completion date: December 31, 2021
• Est. primary completion date: September 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age at least 18 years old

• Have at least 1 underlying non-communicable disease include hypertension, diabetes, dyslipidemia, cardiovascular diseases, cerebrovascular diseases, stable asthma (defined as no asthmatic exacerbation for the preceding 4 weeks necessitating oral prednisolone or an increased use of inhaled corticosteroid, the use of rescue treatment no more than three times a week, and with no clinical indication for change in treatment medication) COPD stage A-C according to GOLD guideline, chronic kidney diseases

• Smoke 10 cigarettes or over per day at least 1 month prior to study

• Desired to quit smoking

• Consent to participate in study

Exclusion Criteria:

• Renal dysfunction (GFR < 30 ml/mins/1.73m2)

• Liver dysfunction (Child-Pugh score C)

• Hyperkalemia (serum potassium = 5 mEq/L)

• Documented of active depression or psychosis

• Active cancer

• History of acute coronary syndrome in previous 4 weeks

• Known case of pregnancy or lactation

• Use other tobacco products or other addictive substances except alcohol

• Use other smoking cessation drugs

Related Conditions & MeSH terms

• Noncommunicable Diseases
• Smoking Cessation

Intervention

Dietary Supplement:
• Vernonia cinerea
Vernonia cinerea is an herb that is claimed in many Thai medicinal formulas. In traditional medicines, they use this herbal to treat diseases such as hypertension, asthma, fever, hepatitis, gallstones, including use to help smoker quit smoking.
• Placebo
Sweetener

Locations

Country	Name	City	State
Thailand	Krittin Bunditanukul	Bangkok

Sponsors (1)

Lead Sponsor	Collaborator
Chulalongkorn University

Country where clinical trial is conducted

Thailand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	continuous abstinence rate	self-report of no cigarette smoking, not even a puff since target quit date, plus passed biochemical validation	1 month
Secondary	continuous abstinence rate (CAR) and point prevalence rate	self-report of no cigarette smoking, not even a puff since target quit date, plus passed biochemical validation	3,6 and 12 months